References

Rheumatoid arthritis

10.1016/s0140-6736(16)30173-8 · 2016 · External reference

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update

10.1136/ard-2022-223356 · 2023 · External reference

Treating rheumatoid arthritis to target: recommendations of an international task force

10.1136/ard.2009.123919 · 2010 · External reference

EULAR definition of difficult-to-treat rheumatoid arthritis

10.1136/annrheumdis-2020-217344 · 2021 · External reference

Difficult-to-treat rheumatoid arthritis: current concept and unsolved problems

10.3389/fmed.2022.1049875 · 2022 · External reference

Clinical predictors of multiple failure to biological therapy in patients with rheumatoid arthritis

10.1186/s13075-020-02354-1 · 2020 · External reference

Rheumatoid factors: clinical applications

10.1155/2013/726598 · 2013 · External reference

Influence of rheumatoid factor levels and TNF inhibitor structure on secondary nonresponse in rheumatoid arthritis patients

10.3389/fmed.2024.1461396 · 2024 · External reference

Differential efficacy of TNF inhibitors with or without the immunoglobulin fragment crystallizable (Fc) portion in rheumatoid arthritis: the ANSWER cohort study

10.1007/s00296-021-05086-w · 2022 · External reference

Ozoralizumab shows effectiveness regardless of baseline RF and ACPA titres in patients with RA: a post hoc analysis of the OHZORA trial

10.1093/rheumatology/keaf171 · 2025 · External reference

Rheumatoid factor: diagnostic and prognostic performance and therapeutic implications in rheumatoid arthritis

10.3390/jcm14051529 · 2025 · External reference

Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement

10.1136/ard.2003.014647 · 2004 · External reference

Does immunological remission, defined as disappearance of autoantibodies, occur with current treatment strategies? A long-term follow-up study in rheumatoid arthritis patients who achieved sustained DMARD-free status

10.1136/annrheumdis-2018-214868 · 2019 · External reference

Rheumatoid factor and anti-cyclic citrullinated peptide antibody levels decline in rheumatoid arthritis patients treated with Janus kinase inhibitors or biological disease-modifying anti-rheumatic drugs

10.4078/jrd.2025.0039 · 2025 · External reference

Rheumatoid factor titer as an indicator of the risk of rheumatoid arthritis activity: dose-effect analysis with the restricted cubic spline model

10.2147/jir.s488605 · 2024 · External reference

Clinical significance of rheumatoid factors in early rheumatoid arthritis: results of a follow up study

10.1136/ard.51.9.1029 · 1992 · External reference

Predictive factors and treatment outcomes associated with difficult-to-treat rheumatoid arthritis conditions: the ANSWER cohort study

10.1093/rheumatology/keae265 · 2024 · External reference

Baseline neutrophil-to-lymphocyte ratio predicts drug retention of IL-6 inhibitors and JAK inhibitors in RA: the ANSWER cohort study

10.1093/rheumatology/keaf602 · 2026 · External reference

The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis

10.1002/art.1780310302 · 1988 · External reference

2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative

10.1136/ard.2010.138461 · 2010 · External reference

Investigation of the freely available easy-to-use software 'EZR' for medical statistics

10.1038/bmt.2012.244 · 2013 · External reference

IL-6 Revisited: from rheumatoid arthritis to CAR T cell therapy and COVID-19

10.1146/annurev-immunol-101220-023458 · 2022 · External reference

Serum TNFalpha levels at 24 h after certolizumab pegol predict effectiveness at week 12 in patients with rheumatoid arthritis from TSUBAME study

10.1186/s13075-021-02547-2 · 2021 · External reference

Role of type I interferons in the activation of autoreactive B cells

10.1038/icb.2012.10 · 2012 · External reference

Interferon-alpha-mediated therapeutic resistance in early rheumatoid arthritis implicates epigenetic reprogramming

10.1136/annrheumdis-2022-222370 · 2022 · External reference

Rheumatoid arthritis: pathogenic roles of diverse immune cells

10.3390/ijms23020905 · 2022 · External reference

Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story

10.1136/ard-2023-223850 · 2024 · External reference

The influence of ACPA status and characteristics on the course of RA

10.1038/nrrheum.2011.204 · 2012 · External reference

Prevalence and predictive factors of difficult-to-treat rheumatoid arthritis: the KURAMA cohort

10.1080/25785826.2021.1928383 · 2022 · External reference

Difficult-to-treat rheumatoid arthritis: what have we learned and what do we still need to learn?

10.1093/rheumatology/keae544 · 2025 · External reference

Characteristics of patients with difficult-to-treat rheumatoid arthritis in clinical practice

10.1093/rheumatology/keab209 · 2021 · External reference

The add-on effectiveness and safety of iguratimod in patients with rheumatoid arthritis who showed an inadequate response to tocilizumab

10.1080/14397595.2018.1486939 · 2019 · External reference